Mitigating Risk in the Supply Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mitigating Risk in the Supply Chain
The author describes the importance of risk management and offers strategies for risk-management preparedness in supply chains.


Pharmaceutical Technology
Volume 34, pp. s22-s28

Elements to assess supply disruption

A simple diagnostic test can assess whether a company is adequately prepared for supply-chain disruptions or mitigating reputational risk. Key questions to consider are:

  • Does a company have a comprehensive supply-chain risk-management program in place?
  • Does the supply-chain risk-management program have well-documented policies and procedures in place that adequately protect the company against the types of issues that are generating enormous news today (e.g., supply-chain disruptions such as geopolitical instability, natural disasters, financial collapse, inconsistent quality, contamination, and counterfeiting; corporate responsibility such as human rights violations and environmental concerns; and employee responsibility such as fraudulent activities, discrimination, and harassment)?
  • Are employees trained and certified in their understanding of these policies on an annual basis?
  • Is there a systematic process and data-management repository in place to ensure rapid and proactive response to unexpected events?
  • Are corporate responsibility and supply-chain risk-management a top priority among the company's senior executives?

The answers to these questions provide insight into whether a company is adequately prepared to mitigate risk in its supply-chain activities.

Gregg Brandyberry is a partner of Wildfire Commerce, senior advisor of AT Kearney procurement and analytic solutions, and former vice-president of procurement, global systems, and operations for GlaxoSmithKline, 629 Overhill Road, Ardmore, PA 19003, tel. 215.327.5739,

References

1. D. Gilmore, Supply Chain Digest, May 7, 2009.

2. FDA, Information on Heparin (Rockville, MD), http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm112597.htm, accessed June 30, 2010.

3. "The 2010 Global 100 List," Corporate Knights, http://www.global100.org/annual-reviews/2010-global-100-list.html, accessed July 15, 2010.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here